Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
Previous close
$0.9305
−$0.0219 · -2.30%
Regular session · ET · Market data may be delayed.
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
Day range
Current $0.9305
52-week range
Current $0.9305
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
41
Mixed
Risk
53
Elevated Risk
Momentum
60
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
Day range
Current $0.9305
52-week range
Current $0.9305
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 42.08M USD | 24.4M USD | 44M USD | 23.69M USD | — |
| Selling, general, and administrative | 33.16M USD | 30.79M USD | 18.64M USD | 3.47M USD | 1.09M USD |
| Operating expenses | 75.25M USD | 55.19M USD | 62.64M USD | 27.16M USD | 1.09M USD |
| Interest income | 6.34M USD | 8M USD | 2.19M USD | 570 USD | 23.48K USD |
| Depreciation and amortization | 49K USD | 9K USD | — | — | — |
| Operating income | −75.25M USD | −55.19M USD | −62.64M USD | −27.16M USD | −1.09M USD |
| Net income | −68.65M USD | −52.4M USD | −60.36M USD | −25.74M USD | 8.42M USD |
Company facts updated Nov 22, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Extended Market ETFVXF2.81M0.00%30.2B USD0.05%$211.44-3.21%
iShares Russell 2000 ETFIWM1.46M0.00%71.54B USD0.19%$256.61-2.88%
Vanguard Russell 2000 ETFVTWO1.41M0.01%16.8B USD0.06%$103.76-2.76%
iShares Russell 2000 Growth ETFIWO534.68K0.00%12.73B USD0.24%$320.43-3.57%
Vanguard U.S. Momentum Factor ETFVFMO510.76K0.03%1.9B USD0.13%$193.88-3.13%
Vanguard Russell 2000 Growth ETFVTWG257.61K0.02%1.4B USD0.06%$234.06-3.57%
iShares Micro-Cap ETFIWC166.11K0.02%1.09B USD0.60%$157.87-3.19%
ALPS Medical Breakthroughs ETFSBIO108.34K0.06%170.88M USD0.50%$50.95-3.01%
Vanguard Extended Market ETFVXF
iShares Russell 2000 ETFIWM
Vanguard Russell 2000 ETFVTWO
iShares Russell 2000 Growth ETFIWO
Vanguard U.S. Momentum Factor ETFVFMO
Vanguard Russell 2000 Growth ETFVTWG
iShares Micro-Cap ETFIWC
ALPS Medical Breakthroughs ETFSBIOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.